CAR vs IOVA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CAR and IOVA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CAR and IOVA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Avis Budget Group runs one of the three big global vehicle-rental platforms, operating the Avis, Budget, Budget Truck, Payless and Zipcar brands across airport, off-airport, urban and international markets. Revenue comes from renting a large owned-and-leased vehicle fleet, and the economics hinge on utilization, per-day pricing and the residual value of cars when they are sold out of the fleet. The company competes with privately held Enterprise Holdings, Hertz, Europe's Sixt, and peer-to-peer platforms like Turo and Getaround.

Full CAR guide

Iovance Biotherapeutics (Nasdaq: IOVA) develops tumor-infiltrating lymphocyte (TIL) cell therapies, individualized treatments made from a patient's own immune cells. Its lead product, Amtagvi (lifileucel), became the first FDA-approved one-time T-cell therapy for a solid tumor when it was cleared for advanced melanoma, and the company also sells Proleukin, an interleukin-2 product used alongside TIL treatment. Iovance manufactures Amtagvi in-house at its Iovance Cell Therapy Center and has treated more than 1,500 patients across commercial and clinical use, with expanding regulatory approvals including a conditional nod in Australia.

Full IOVA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CAR drivers: Fleet utilization and pricing recovery; Vehicle residual values and fleet mix.
• IOVA drivers: Amtagvi commercial ramp; In-house manufacturing and margin scale.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The equity is small relative to enormous fleet and corporate debt, so modest swings in used-car residual values, interest rates or demand can move the stock sharply, and the shares carry a beta well above the market. For IOVA, iovance remains unprofitable and has historically funded operations with stock sales, so ongoing dilution is a real risk to existing shareholders.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CAR if you believe its drivers more; IOVA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CAR and IOVA guides.

CAR. CAR does not screen on a simple price-to-earnings basis because trailing earnings per share are negative, so investors lean on enterprise-value-to-EBITDA and the path back toward the company's roughly $1 billion adjusted EBITDA goal. With about 35 million shares outstanding and negative book equity, the stock behaves like a leveraged call on the rental cycle. Figures are approximate and drawn from the company's 2025 full-year and first-quarter 2026 disclosures.

IOVA. Iovance trades at roughly five times trailing revenue, a multiple that reflects rapid growth expectations rather than current earnings, since the company is still posting net losses. Losses have been narrowing year over year as Amtagvi revenue scales and margins improve. Valuation ultimately hinges on whether the revenue ramp and margin expansion continue toward eventual profitability.

Headline figures (approximate, JULY 2026): CAR shows revenue (fy2025) ~$11.7B, revenue (q1 2026) ~$2.53B, up ~4% YoY, net loss (fy2025) ~$995M, adjusted ebitda (fy2025) ~$748M; IOVA shows revenue (ttm) ~$285M, fy2026 revenue guidance ~$350M to $370M, market cap ~$1.4B, cash (q1 2026) ~$319M.

CAR and IOVA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CAR and IOVA exposure against your real portfolio. It is not an investment adviser.